Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Randomised Multicentre Phase III Study Of Irinotecan Hydrochloride (Campto (Registered)) And Cisplatin Versus Etoposide And Cisplatin In Chemotherapy Naive Patients With Extensive Disease - Small Cell Lung Cancer

NCT00143455 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00143455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00143455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Randomised Multicentre Phase III Study Of Irinotecan Hydrochloride (Campto (Registered)) And Cisplatin Versus Etoposide And Cisplatin In Chemotherapy Naive Patients With Extensive Disease - Small Cell Lung Cancer
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2002
Completion date
December 31, 2008
Enrollment
485 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma